A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Corpus Uteri | Larynx | Lung | Soft Tissue | Unknown Sites
What is the purpose of this trial?
This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in adult subjects with metastatic solid tumors with elevated Trop-2 expression.
- Trial withImmunomedics, Inc.
- Start Date08/23/2021
- End Date04/30/2022
- Last Updated08/24/2021
- Study HIC#2000025243